
SPARK Microgravity Completes Integration Campaign at SSC in Sweden Ahead of First SubOrbital Express Flight
SPARK Microgravity has successfully completed its integration campaign with Swedish Space Corporation (SSC).

Davos, Switzerland — January 2026 — SPARK Microgravity joined global scientific and industry leaders at Frontiers Science House in Davos to help shape one of the most important conversations emerging at the intersection of biotechnology, oncology, and space infrastructure: how microgravity can open a new frontier for cancer research.
As part of the session “Curing Cancer in Space,” SPARK Microgravity’s founders, Allison Bajet and Katharina Weidmann, contributed the company’s perspective on why real microgravity should no longer be viewed as a scientific novelty, but as a strategically valuable research environment for oncology. Their participation marked an important milestone for the company, bringing SPARK’s mission into an international forum focused on the future of science, health, and global decision-making.
SPARK Microgravity is building toward a future in which researchers and pharmaceutical partners can run highly controlled cancer biology experiments in orbit through a dedicated commercial platform designed specifically for this purpose. The company’s vision is grounded in a simple but consequential insight: gravity shapes biology more deeply than most conventional research systems account for. When gravity is removed as a dominant force, cells organize, communicate, and respond in materially different ways. For cancer research, that creates the possibility of observing disease behavior, tumor architecture, and treatment response through a new lens — one that may reveal biology that Earth-based models can obscure.
At Frontiers Science House, SPARK used the moment not only to communicate its long-term ambition, but to place that ambition in a broader scientific and commercial context. The discussion reflected a growing recognition that microgravity can serve as a meaningful research tool for life sciences, particularly in areas where three-dimensional cell behavior, tissue-like organization, and therapeutic response matter. In oncology, where model quality can directly influence development decisions, that shift has potentially profound implications.
For SPARK, the significance of the session went beyond visibility. It represented external validation that the company’s thesis belongs in serious, cross-disciplinary conversations among scientists, policymakers, entrepreneurs, and institutional leaders. It also underscored an important evolution in the way space-based biomedical infrastructure is being understood: not as an experimental side path, but as a practical capability with growing relevance to human health.
“Curing cancer will require better tools, better models, and new environments in which to understand disease,” said Allison Bajet, Co-Founder and CEO of SPARK Microgravity. “Our belief is that microgravity can become one of those environments — not as spectacle, but as infrastructure. We are building SPARK to make that infrastructure accessible, repeatable, and useful to the scientists working on some of the hardest problems in oncology.”
Katharina Weidmann, Co-Founder and COO, emphasized the importance of translating a frontier scientific idea into an operationally viable platform. “What matters is not only the vision, but the ability to execute it in a way that researchers can trust and use,” she said. “Our focus is to build a system that enables structured, high-quality biology in orbit — in a format that supports real scientific progress and, over time, real commercial adoption.”
SPARK’s presence at Frontiers Science House reflects a broader momentum around the company as it continues to develop its orbital oncology platform, expand its external visibility, and engage with leading stakeholders across both biotech and space. By joining the discussion in Davos, the company reinforced its conviction that the future of cancer research will not be defined only by new molecules or new data layers, but also by new environments in which biology can be observed more truthfully.
For SPARK Microgravity, that future is no longer abstract. It is taking shape now.

SPARK Microgravity has successfully completed its integration campaign with Swedish Space Corporation (SSC).

SPARK Microgravity Brings Orbital Oncology Vision to ORBIT FOR LIFE Roundtable at Roche Diagnostics